{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003919","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.896616+00:00","generated_at":"2026-06-28T10:04:47.615916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio Q3 net loss $10.2M ($0.37/share); cash $187M; pipeline on track","bullets":["Net loss $10.2M vs $7.2M in Q3 2020; R&D $5.0M flat; G&A $5.0M up from $1.6M.","Cash and equivalents $187.0M, including $83M net from August 2021 IPO.","Initiated FNAIT natural history study to support RLYB212 registration trial design.","On-track to report additional Phase 1/2 RLYB211 data in Q4 2021.","Phase 1 studies for RLYB212 and RLYB116 expected to start in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003919","json":"https://secwatch.observer/filing/0000950170-21-003919.json","markdown":"https://secwatch.observer/filing/0000950170-21-003919.md","text":"https://secwatch.observer/filing/0000950170-21-003919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/0000950170-21-003919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/rlyb-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:04:47.615916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}